Investor Relations

Latest Financial Results

FY 2021

Fiscal Year Ended Dec 31, 2021

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com

Stock Snapshot

XORTX Therapeutics Inc.

View Detailed Stock Information

IR Contacts

Company

XORTX Therapeutics Inc.
3710 – 33rd Street NW
Calgary, Alberta T2L 2M1
Canada
T: 403-455-7727
info@xortx.com

Investor Relations

Allen Davidoff
CEO
T: 403-455-7727
adavidoff@xortx.com

Nick Rigopulos
Director of Communications
T: 617-901-0785
nick@alpineequityadv.com

Transfer Agent

TSX Trust Company
Investor Services
100 Adelaide Street West
Suite 301
Toronto, ON M5H 4H1
Canada
T: 416-342-1091
tmxeinvestorservices@tmx.com